{"entity":{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","aka":[],"tldr":"A phase 1/2 trial of STX-721/PFL-721 (Escalated) in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.","summary":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations is a phase 1/2 interventional study registered as NCT06043817 by Pierre Fabre Medicament, with 345 participants planned, started 2023-09-26 and due to reach its primary completion in 2029-12-01. Interventions recorded: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels) and STX-721/PFL-721 (RP2D).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06043817","url":"https://clinicaltrials.gov/study/NCT06043817"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc","her2-mutant-nsclc"],"sections":[],"technologies":[],"targets":["her2","egfr"],"drugs":[],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06043817","phase":"1/2","setting":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","sponsor":"Pierre Fabre Medicament","started":"2023-09-26","startedType":"actual","enrolled":345,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06043817/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}]}}